Post-treatment sarcoma in breast cancer patients.
Identifieur interne : 004E24 ( PubMed/Checkpoint ); précédent : 004E23; suivant : 004E25Post-treatment sarcoma in breast cancer patients.
Auteurs : M S Brady [États-Unis] ; C F Garfein ; J A Petrek ; M F BrennanSource :
- Annals of surgical oncology [ 1068-9265 ] ; 1994.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Bras, Femelle, Fibrosarcome (mortalité), Fibrosarcome (étiologie), Humains, Lymphangiosarcome (mortalité), Lymphangiosarcome (étiologie), Mâle, Pronostic, Radiothérapie (effets indésirables), Sarcomes (étiologie), Seconde tumeur primitive (), Sujet âgé, Taux de survie, Tumeur du sein de l'homme (radiothérapie), Tumeurs du sein (radiothérapie), Tumeurs radio-induites.
- MESH :
- effets indésirables : Radiothérapie.
- mortalité : Fibrosarcome, Lymphangiosarcome.
- radiothérapie : Tumeur du sein de l'homme, Tumeurs du sein.
- étiologie : Fibrosarcome, Lymphangiosarcome, Sarcomes.
- Adulte, Adulte d'âge moyen, Bras, Femelle, Humains, Mâle, Pronostic, Seconde tumeur primitive, Sujet âgé, Taux de survie, Tumeurs radio-induites.
English descriptors
- KwdEn :
- Adult, Aged, Arm, Breast Neoplasms (radiotherapy), Breast Neoplasms, Male (radiotherapy), Female, Fibrosarcoma (etiology), Fibrosarcoma (mortality), Humans, Lymphangiosarcoma (etiology), Lymphangiosarcoma (mortality), Male, Middle Aged, Neoplasms, Radiation-Induced, Neoplasms, Second Primary (therapy), Prognosis, Radiotherapy (adverse effects), Sarcoma (etiology), Survival Rate.
- MESH :
- adverse effects : Radiotherapy.
- etiology : Fibrosarcoma, Lymphangiosarcoma, Sarcoma.
- mortality : Fibrosarcoma, Lymphangiosarcoma.
- radiotherapy : Breast Neoplasms, Breast Neoplasms, Male.
- therapy : Neoplasms, Second Primary.
- Adult, Aged, Arm, Female, Humans, Male, Middle Aged, Neoplasms, Radiation-Induced, Prognosis, Survival Rate.
Abstract
Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years.
PubMed: 7834431
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:7834431Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Post-treatment sarcoma in breast cancer patients.</title><author><name sortKey="Brady, M S" sort="Brady, M S" uniqKey="Brady M" first="M S" last="Brady">M S Brady</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Garfein, C F" sort="Garfein, C F" uniqKey="Garfein C" first="C F" last="Garfein">C F Garfein</name></author><author><name sortKey="Petrek, J A" sort="Petrek, J A" uniqKey="Petrek J" first="J A" last="Petrek">J A Petrek</name></author><author><name sortKey="Brennan, M F" sort="Brennan, M F" uniqKey="Brennan M" first="M F" last="Brennan">M F Brennan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7834431</idno><idno type="pmid">7834431</idno><idno type="wicri:Area/PubMed/Corpus">005622</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005622</idno><idno type="wicri:Area/PubMed/Curation">005622</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005622</idno><idno type="wicri:Area/PubMed/Checkpoint">005622</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005622</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Post-treatment sarcoma in breast cancer patients.</title><author><name sortKey="Brady, M S" sort="Brady, M S" uniqKey="Brady M" first="M S" last="Brady">M S Brady</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Garfein, C F" sort="Garfein, C F" uniqKey="Garfein C" first="C F" last="Garfein">C F Garfein</name></author><author><name sortKey="Petrek, J A" sort="Petrek, J A" uniqKey="Petrek J" first="J A" last="Petrek">J A Petrek</name></author><author><name sortKey="Brennan, M F" sort="Brennan, M F" uniqKey="Brennan M" first="M F" last="Brennan">M F Brennan</name></author></analytic><series><title level="j">Annals of surgical oncology</title><idno type="ISSN">1068-9265</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Arm</term><term>Breast Neoplasms (radiotherapy)</term><term>Breast Neoplasms, Male (radiotherapy)</term><term>Female</term><term>Fibrosarcoma (etiology)</term><term>Fibrosarcoma (mortality)</term><term>Humans</term><term>Lymphangiosarcoma (etiology)</term><term>Lymphangiosarcoma (mortality)</term><term>Male</term><term>Middle Aged</term><term>Neoplasms, Radiation-Induced</term><term>Neoplasms, Second Primary (therapy)</term><term>Prognosis</term><term>Radiotherapy (adverse effects)</term><term>Sarcoma (etiology)</term><term>Survival Rate</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bras</term><term>Femelle</term><term>Fibrosarcome (mortalité)</term><term>Fibrosarcome (étiologie)</term><term>Humains</term><term>Lymphangiosarcome (mortalité)</term><term>Lymphangiosarcome (étiologie)</term><term>Mâle</term><term>Pronostic</term><term>Radiothérapie (effets indésirables)</term><term>Sarcomes (étiologie)</term><term>Seconde tumeur primitive ()</term><term>Sujet âgé</term><term>Taux de survie</term><term>Tumeur du sein de l'homme (radiothérapie)</term><term>Tumeurs du sein (radiothérapie)</term><term>Tumeurs radio-induites</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radiotherapy</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Radiothérapie</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fibrosarcoma</term><term>Lymphangiosarcoma</term><term>Sarcoma</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Fibrosarcoma</term><term>Lymphangiosarcoma</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Fibrosarcome</term><term>Lymphangiosarcome</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term><term>Breast Neoplasms, Male</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeur du sein de l'homme</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms, Second Primary</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Fibrosarcome</term><term>Lymphangiosarcome</term><term>Sarcomes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Arm</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasms, Radiation-Induced</term><term>Prognosis</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bras</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pronostic</term><term>Seconde tumeur primitive</term><term>Sujet âgé</term><term>Taux de survie</term><term>Tumeurs radio-induites</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7834431</PMID><DateCreated><Year>1995</Year><Month>03</Month><Day>02</Day></DateCreated><DateCompleted><Year>1995</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1068-9265</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>1994</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of surgical oncology</Title><ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Post-treatment sarcoma in breast cancer patients.</ArticleTitle><Pagination><MedlinePgn>66-72</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4-44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p < 0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p = 0.98).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garfein</LastName><ForeName>C F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Petrek</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA 47179</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg Oncol</MedlineTA><NlmUniqueID>9420840</NlmUniqueID><ISSNLinking>1068-9265</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1982 Oct 23;2(8304):924</RefSource><PMID Version="1">6126762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1986 Feb 1;57(3):610-5</RefSource><PMID Version="1">3942997</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Radiol Oncol. 1986 Jul-Dec;25(4-6):239-42</RefSource><PMID Version="1">3030050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1972 Aug;30(2):562-72</RefSource><PMID Version="1">5051679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiology. 1978 Nov;129(2):501-8</RefSource><PMID Version="1">279941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1981 Oct 1;48(7):1674-9</RefSource><PMID Version="1">7284967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1987 Aug;5(8):1138-42</RefSource><PMID Version="1">3625243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Natl Cancer Inst Monogr. 1985 Dec;68:99-112</RefSource><PMID Version="1">4088315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1948 May;1(1):64-81</RefSource><PMID Version="1">18867440</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1979 Jan;43(1):182-7</RefSource><PMID Version="1">367566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1984 Dec 1;54(11):2319-23</RefSource><PMID Version="1">6498728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Surg. 1992 Dec;127(12):1379-85</RefSource><PMID Version="1">1365680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7</RefSource><PMID Version="1">1648044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Rep. 1966 Mar;50(3):163-70</RefSource><PMID Version="1">5910392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Radiol. 1991 Sep;64(765):857-60</RefSource><PMID Version="1">1913053</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Clin North Am. 1962 Jul;46:1045-50</RefSource><PMID Version="1">14498466</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Orthop Clin North Am. 1977 Oct;8(4):821-34</RefSource><PMID Version="1">270086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1981 Mar 1;47(5):853-6</RefSource><PMID Version="1">7226038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Res. 1982 May;90(2):395-432</RefSource><PMID Version="1">7079470</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="N">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005354" MajorTopicYN="N">Fibrosarcoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008204" MajorTopicYN="N">Lymphangiosarcoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009381" MajorTopicYN="Y">Neoplasms, Radiation-Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="Y">Neoplasms, Second Primary</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012509" MajorTopicYN="N">Sarcoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7834431</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Brennan, M F" sort="Brennan, M F" uniqKey="Brennan M" first="M F" last="Brennan">M F Brennan</name><name sortKey="Garfein, C F" sort="Garfein, C F" uniqKey="Garfein C" first="C F" last="Garfein">C F Garfein</name><name sortKey="Petrek, J A" sort="Petrek, J A" uniqKey="Petrek J" first="J A" last="Petrek">J A Petrek</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Brady, M S" sort="Brady, M S" uniqKey="Brady M" first="M S" last="Brady">M S Brady</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004E24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:7834431
|texte= Post-treatment sarcoma in breast cancer patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:7834431" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |